Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast03: Dato-DXd With or Without Durvalumab vs Investigator's Choice in Stage I-III TNBC
NCT05629585Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of datopotamab deruxtecan in triple-negative breast cancer (TNBC), sponsored by AstraZeneca. Started Nov 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05629585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05629585.